RxDoctor Payments Data

Hedieh Davanloo, MD

Internal Medicine · Arlington, TXNPI 1659567758

Payments from drug & device makers

$2,949in general payments, 2019–2025

Across 63 payments — averaging $46.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Bayer$500
  • AbbVie$351
  • Bristol Myers Squibb$232
  • Lilly USA, LLC$216
  • Amgen$84
  • plus $121 from 5 others

What the payments were for

  • Food & beverage$2,949100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott13$1,445
Bayer5$500
AbbVie(2 entities)19$351
Bristol Myers Squibb11$232
Lilly USA, LLC3$216
Amgen5$84
Exact Sciences3$53
Promius Pharma LLC1$23
Mylan Specialty L.p.1$21
Astellas Pharma US Inc1$13
Teva Pharmaceuticals USA, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,949 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$4,536
Medicare patients
57
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$146,507
RinvoqUpadacitinib14$92,399
OzempicSemaglutide61$86,201
MounjaroTirzepatide47$60,026
JardianceEmpagliflozin24$48,246
MyrbetriqMirabegron27$35,195
JanuviaSitagliptin Phosphate25$33,076
TrulicityDulaglutide17$21,777
SymbicortBudesonide/Formoterol Fumarate47$16,653
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$13,618
Lantus SolostarInsulin Glargine,hum.Rec.Anlog60$10,781
Humalog Kwikpen U-100Insulin Lispro25$10,056
LantusInsulin Glargine,hum.Rec.Anlog50$9,426
CreonLipase/Protease/Amylase11$8,869
Atorvastatin Calcium746$5,322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Creon, Synthroid$351$102,54936 claims
Lilly USA, LLCMounjaro, Trulicity$216$81,80364 claims
Astellas Pharma US IncMyrbetriq$13$35,19527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →